Immix Biopharma
sizable relapsed refractory amyloidosis patient population immix | Immix Biopharma
Company
Deck Type
Sector
Industry
Deck date
March 2024
Slide
26 of 56
Related slides by other companies
Neumora Therapeutics
IPO
September 2023
phase efficacy population patient demographics and characteristics similar across treatment groups | Neumora Therapeutics
Ocuphire Pharma
Results
June 2021
patient population subject disposition | Ocuphire Pharma
Genelux
Investor Presentation
February 2024
primed anti tumor activity primed | Genelux
Dynacure
IPO
July 2021
our population is of patients in the | Dynacure
Other recent decks by Immix Biopharma
See all presentations (11 decks)
Investor Presentation
January 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights